Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL17309997 | 0.88 | CYP2C9 (0.32) | ALDH1A1TSHR | |
| 2-Ethoxyethanol SCHEMBL9805604 | 0.82 | ALDH1A1 (0.58) | ACHEEPHX1KMT2AALDH1A1TSHR | |
| Biphenyl SCHEMBL2037133 | 0.80 | ALDH1A1 (0.47) | SHBGCYP1A2EPHX1ALDH1A1L3MBTL1 | |
| Ether SCHEMBL8824885 | 0.80 | ALDH1A1 (0.47) | SHBGCYP1A2EPHX1ALDH1A1L3MBTL1 | |
| Ether SCHEMBL9725961 | 0.80 | ALDH1A1 (0.47) | SHBGCYP1A2EPHX1ALDH1A1L3MBTL1 | |
| Methylcyclopentane SCHEMBL1490916 | 0.78 | — | — | |
| Cycloheptane SCHEMBL23885013 | 0.78 | ACHE (0.43) | ACHESHBGCYP1A2EPHX1KMT2A | |
| Cyclopentane SCHEMBL8923462 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL5189 | 0.78 | — | — | |
| Cyclohexane SCHEMBL2297628 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202651-A1 | POLYMORPHIC FORMS OF GLUTAMINE ANTAGONIST AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | claimed |
| EP-0645398-B1 | METHOD OF CRYSTALLIZING N?2 -((S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL)-N?6 -TRIFLUOROACETYL-L-LYSYL-L-PROLINE | KANEGAFUCHI CHEMICAL IND (JP) | 2003-03-05 | — | — | EP | claimed |
| WO-2023202651-A1 | POLYMORPHIC FORMS OF GLUTAMINE ANTAGONIST AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | disclosed |
| CN-107922443-A | Sulfur-containing organosilicon compounds and resin combination | 株式会社可乐丽 | 2018-04-17 | — | — | CN | disclosed |
| CN-107922444-A | Organic silicon compound, polymer compound, inorganic material, and resin composition | 株式会社可乐丽 | 2018-04-17 | — | — | CN | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0828815-A1 | AZEOTROPE-LIKE COMPOSITIONS AND THEIR USE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996036689-A1 | AZEOTROPE-LIKE COMPOSITIONS AND THEIR USE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | ACHE 4859/4885SHBG 3446/4885CYP1A2 1487/4885 |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | ACHE 1215/4885SHBG 455/4885CYP1A2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.